Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,130.7
28.8 (0.93%)

 

  • STI Straits Times Index
    3,130.7
    28.8 (0.93%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,490.5
    -11.2 (-0.75%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    23,444.2
    -322.5 (-1.36%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,611.2
    3.8 (0.11%)
    Index delayed 15 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 547.5M
  • Value: 495.9M
  • Rise: 141
  • Fall: 138
  • Unch: 482

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Addvalue Tech0.016+0.003
HGH0.016-0.003
Hatten Land0.048-0.004
DigiCore Reit USD1.000+1.000
Sembcorp Marine0.084+0.001
Singtel2.410+0.030
CapLand IntCom T2.050-0.010
Genting Sing0.775+0.015
ThaiBev0.670+0.005
DISA0.002+0.001

World Indices

World Indices
Name Last Change
Nasdaq 15,085.5 -295.9
HSI 23,446.0 -320.6
HSCEI 8,308.7 -146.8
Jakarta 6,573.4 +34.9
Nikkei 225 27,935.6
SSE Comp 3,611.2 +3.8
Shanghai A 3,785.1 +4.2
Shanghai B 282.3 -3.6
KOSPI 2,974.8 +6.5

Nikkei 225 updated at end-of-day. Other Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

IX Biopharma IX BIOPHARMA LTD.
Quotes 10 Minutes Delayed. Updated at 06 Dec 2021 13:54
Last (SGD): 0.225 Change: - High: 0.225 Remarks: -
Change (%): - Low: 0.225

Company Background

iX Biopharma is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Singapore Exchange Securities Trading Limited (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery. iX Biopharma’s pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharma’s drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia. iX Biopharma has developed Xativa, the world’s first freeze-dried sublingual medicinal cannabis wafer. The Group’s nutraceuticals division, Entity Health Limited, is engaged in the development and commercialisation of nutraceutical products that address specific conditions and improve quality of life. It distributes its Entity line of nutraceutical products in Australia through more than 250 pharmacies and health food shops, in China through its flagship stores on Tmall Global and JD Worldwide, and globally through its online store.

Click to show Stock Prices chart

Key Statistics

EPS (SGD) a -0.01104 Trailing EPS (SGD) b -0.01104 NAV (SGD) c 0.0288
PE a - Trailing PE d - Price / NAV c 7.8125
Dividend Yield (%) e - Cash In Hand (SGD) f 0.0075 Issued & Paid-up Shares g 746,168,000
Piotroski F Score 2 Market Cap (M) 167.888 Free Float (%) 49.9
Return on Equity (ROE) (%) h n.m. Revenue Growth (%) TTM i 77.157
Net Earnings Growth (%) j 21.573 Net Debt/Equity k Net Cash
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Prof, Scientific & Technical Activities - Pharmaceuticals: Major
Category Classification Medical & Biotechnology
Index Components FTSE ST Catalist Index
Notes:
  1. Based on latest Full Year results announcement, adjusted based on Profit Attributable To Shareholders.
  2. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  3. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  4. Based on latest Full Year results announcement, adjusted for the current number of shares.
  5. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  6. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  7. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 23 Nov 2021. Please click here for more information.
  8. Calculated based on Net Earnings / (Shareholders' Equity - Other Share Capital)
  9. Calculated based on (Current Year Revenue - Last Year Revenue) / Last Year Revenue
  10. Calculated based on (Current Year Earnings - Last Year Earnings) / Last Year Earnings
  11. Calculated based on (Long Term Debt + Short Term Debt - Cash and Short Term Investments)/(Shareholders' Equity - Other Share Capital)

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.005
-2.17 %
10 Days --0.010
-4.26 %
20 Days --0.015
-6.25 %
Medium Term Return 3 Months --0.005
-2.17 %
6 Months --0.017
-7.02 %
1 Year --0.012
-5.06 %
Long Term Return 2 Years --0.022
-8.91 %
3 Years -+0.057
+33.93 %
5 Years --0.081
-26.47 %
Annualised Return Annualised --
-5.96 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference IX Biopharma SGX 167.888 - - 7.8125 -
Industry Medical & Biotechnology SGX 1,035.093 19.103 16.236 1.4844 1.899
Pharmaceuticals: Major SGX 87.307 2431.015 115.115 3.5891 0.711
Index FTSE ST Catalist Index SGX 60.472 26.304 20.637 1.3796 2.009
Local Peer Hyphens Pharma SGX 91.089 14.780 14.701 1.8357 2.045
Local Peer Pharmesis Intl SGX 2.944 - - 0.2525 -
Global Peer JOHNSON & JOHNSON NYSE 419,583.788 28.516 23.467 5.9709 2.497
Global Peer PFIZER INC NYSE 304,610.455 31.677 15.882 4.0244 2.796
Global Peer ELI LILLY AND COMPANY NYSE 234,919.863 37.929 39.334 30.2849 1.205
Global Peer ABBVIE INC NYSE 210,112.538 46.118 28.180 15.5066 4.066
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 194,753.600 24.127 19.859 3.4305 2.410
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 189,805.725 29.455 25.569 18.4205 1.256
Global Peer MERCK & CO INC NYSE 185,252.440 26.214 25.740 5.1755 3.387
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 168,021.894 52.572 114.223 4.2276 2.141
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 125,010.688 - - 3.3593 3.303
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 118,948.243 8.474 17.176 1.5861 2.876
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), WUXI APPTEC CO LTD (HKEx), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), ROYALTY PHARMA PLC (NASDAQ), VIATRIS INC (NASDAQ), REPLIGEN CORP (NASDAQ), HANSOH PHARMACEUTICAL GROUP CO LTD (HKEx), INNOVENT BIOLOGICS INC (HKEx), CUREVAC NV (NASDAQ), EVOTEC SE SPON ADS EACH REP 0.50 ORD SHS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), ORGANON & CO (NYSE), SINOPHARM GROUP CO. LTD. (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), CANSINO BIOLOGICS INC (HKEx), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), REMEGEN CO LTD (HKEx), HUTCHMED (CHINA) LIMITED (HKEx), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), SHANGHAI JUNSHI BIOSCIENCES CO LTD (HKEx), SHANGHAI PHARMACEUTICALS HOLDING CO (HKEx), HYGEIA HEALTHCARE HLDGS CO LTD (HKEx), AKESO INC (HKEx), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), ALLAKOS INC (NASDAQ), APELLIS PHARMACEUTICALS INC (NASDAQ), CHINA MEDICAL SYSTEM HLDGS LTD (HKEx), GUANGZHOU BAIYUNSHAN PHARMACEUTICAL (HKEx), INNOCARE PHARMA LTD (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), SIMCERE PHARMACEUTICAL GRP LTD (HKEx), DICERNA PHARMACEUTICALS INC. (NASDAQ), CARSGEN THERAPEUTICS HLDGS LTD (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), GRAND PHARMACEUTICAL GROUP LTD (HKEx), CHINA RESOURCES PHARMACEUTICAL GR (HKEx), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), OPKO HEALTH INC (NASDAQ), CHINA TRADITIONAL CHINESE MED HLDGS (HKEx), IMMUNITYBIO INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), SHANGHAI HENLIUS BIOTECH INC (HKEx), TURNING POINT THERAPEUTICS INC (NASDAQ), CLOVER BIOPHARMACEUTICALS LTD (HKEx), ERASCA INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), ADC THERAPEUTICS SA (NYSE), IGM BIOSCIENCES INC (NASDAQ), SHENZHEN HEPALINK PHARMACEUTICAL (HKEx), CSTONE PHARMACEUTICALS (HKEx), SSY GROUP LIMITED (HKEx), QUANTERIX CORPORATION (NASDAQ), OCUMENSION THERAPEUTICS (HKEx), EVEREST MEDICINES LTD (HKEx), KEROS THERAPEUTICS INC (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), NURIX THERAPEUTICS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), BEIJING TONG REN TANG CHINESE MEDIC (HKEx), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), PROCAPS GROUP S.A. (NASDAQ), UNITED LABORATORIES INTL HLDGS LTD (HKEx), Kimia Farma Tbk. (IDX), IMMUNOTECH BIOPHARM LTD (HKEx), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), GH RESEARCH PLC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), ABBISKO CAYMAN LTD (HKEx), CK LIFE SCIENCES INTL HLDG (HKEx), REPARE THERAPEUTICS INC (NASDAQ), ANTENGENE CORP LTD (HKEx), ZYMEWORKS INC (NYSE), KINNATE BIOPHARMA INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), GENERATION BIO CO (NASDAQ), ICOSAVAX INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), SCICLONE PHARMACEUTICALS (HLDGS) LT (HKEx), SUTRO BIOPHARMA INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), CHINA SHINEWAY PHARMACEUTICAL GR (HKEx), FORMA THERAPEUTICS HLDGS INC (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), PETIQ INC (NASDAQ), KRONOS BIO INC (NASDAQ), 2SEVENTY BIO INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), ANNEXON INC (NASDAQ), Soho Global Health Tbk. (IDX), PHATHOM PHARMACEUTICALS INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), HUA MEDICINE (HKEx), EYEPOINT PHARMACEUTICALS INC (NASDAQ), PHARVARIS NV (NASDAQ), VERU INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), ZHAOKE OPHTHALMOLOGY LTD (HKEx), TRANSCENTA HOLDING LTD (HKEx), IGBB (Bursa), PROVENTION BIO INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), PYXIS ONCOLOGY INC (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), TRICIDA INC (NASDAQ), AC IMMUNE SA (NASDAQ), RACE ONCOLOGY LTD (ASX), MINK THERAPEUTICS INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), XILIO THERAPEUTICS INC (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), CLENE INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), PYC THERAPEUTICS LIMITED (ASX), COMPASS THERAPEUTICS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), DAWNRAYS PHARMACEUTICAL HLDGS (HKEx), TOT BIOPHARM INTL CO LTD (HKEx), KALVISTA PHARMACEUTICALS INC (NASDAQ), EVOLUS INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), BROOKLYN IMMUNO THERAPEUTICS INC (NASDAQ), BSTEAD (Bursa), 89BIO INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), PHARMA (Bursa), HARROW HEALTH INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), XOMA CORP (NASDAQ), CHINA BIOTECH SERVICES HLDGS LTD (HKEx), CHECKPOINT THERAPEUTICS INC (NASDAQ), CYBIN INC (NYSE American), CITIUS PHARMACEUTICALS INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), IMMUNIC INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), VINCERX PHARMA INC (NASDAQ), DURECT CORP (NASDAQ), FUSEN PHARMACEUTICAL CO LTD (HKEx), IMPEL NEUROPHARMA INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), TFF PHARMACEUTICALS INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), ANNOVIS BIO INC (NYSE), MUSTANG BIO INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), ATHENEX INC (NASDAQ), OBSEVA SA (NASDAQ), ALZAMEND NEURO INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), IP (SET), INOZYME PHARMA INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), BEYONDSPRING INC (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), NEXIMMUNE INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), POLYPID LTD (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), Merck Tbk. (IDX), AYALA PHARMACEUTICALS INC (NASDAQ), ZHONGZHI PHARMACEUTICAL HLDGS LTD (HKEx), KALA PHARMACEUTICALS INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), JOURNEY MEDICAL CORPORATION (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), SCPHARMACEUTICALS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), KOTRA (Bursa), PROPHASE LABS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), EYENOVIA INC (NASDAQ), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), JP (SET), PHASEBIO PHARMACEUTICALS INC (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), NEW RAY MEDICINE INTL HLDG LTD (HKEx), ENTERA BIO LTD (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), NOXOPHARM LTD (ASX), NEUBASE THERAPEUTICS INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), NOVAN INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), ABVC BIOPHARMA INC (NASDAQ), CRESO PHARMA LTD (ASX), APREA THERAPEUTICS INC (NASDAQ), INVION LTD (ASX), CHARMACY PHARMACEUTICAL CO LTD (HKEx), CYCLERION THERAPEUTICS INC (NASDAQ), LANNETT CO INC (NYSE), IMARA INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), NOVA (Bursa), EDESA BIOTECH INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), Phapros Tbk. (IDX), MANNATECH INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), PAK FAH YEOW INTERNATIONAL (HKEx), MEDIWOUND LTD (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), GENPREX INC (NASDAQ), NEW CENTURY HEALTHCARE HLDGS CO LTD (HKEx), OCUPHIRE PHARMA INC (NASDAQ), PASITHEA THERAPEUTICS CORP (NASDAQ), GALECTO INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), SYNAPTOGENIX INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), RENOVORX INC (NASDAQ), SANAI HEALTH INDUSTRY GP CO LTD (HKEx), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), WAI YUEN TONG MEDICINE HOLDINGS LTD (HKEx), AILERON THERAPEUTICS INC (NASDAQ), BIOHLDG (Bursa), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), BIOFRONTERA INC (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), MODERN CHINESE MEDICINE GRP CO LTD (HKEx), EXOPHARM LTD (ASX), PALLA PHARMA LTD (ASX), GRAYBUG VISION INC (NASDAQ), SHENZHEN NEPTUNUS INTERLONG BIO-TEC (HKEx), VIRPAX PHARMA INC (NASDAQ), PETROS PHARMACEUTICALS INC (NASDAQ), ACURX PHARMACEUTICALS INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), VIRIOS THERAPEUTICS INC (NASDAQ), PURAPHARM CORPORATION LIMITED (HKEx), PHARMAXIS (ASX), BONE BIOLOGICS CORP (NASDAQ), MEDLAB CLINICAL LIMITED (ASX), UNIVERSE PHARMACEUTICALS INC (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), VALLON PHARMACEUTICALS INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), JCT (SET), EXTRAWELL PHARMACEUTICAL HLDGS (HKEx), ARIDIS PHARMACEUTICAL INC (NASDAQ), SEQLL INC (NASDAQ), BAUDAX BIO INC (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), SUNZEN (Bursa), ACER THERAPEUTICS INC (NASDAQ), XORTX THERAPEUTICS INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), TISSUE REPAIR LTD (ASX), TIMBER PHARMACEUTICALS INC (NYSE American), ONCOSIL MEDICAL LIMITED (ASX), PANBELA THERAPEUTICS INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), TREVI THERAPEUTICS INC (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), ACRUX (ASX), NANJING SINOLIFE UNITED COMPANY LTD (HKEx), DERMATA THERAPEUTICS INC (NASDAQ), IMMURON LIMITED (ASX), HOTH THERAPEUTICS INC (NASDAQ), PAINREFORM LTD (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ISLAND PHARMACEUTICALS LTD (ASX), NLS PHARMACEUTICS LTD (NASDAQ), BIOME AUSTRALIA LT (ASX), TALI DIGITAL LIMITED (ASX), TITAN PHARMACEUTICAL INC (NASDAQ), AROVELLA THERAPEUTICS LTD (ASX), PA SHUN INTERNATIONAL HOLDINGS LTD (HKEx), FIJI KAVA LTD (ASX), CHINA SXT PHARMACEUTICALS INC (NASDAQ), FARMAFORCE LTD (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

More Information Available

More information is available to our subscribers, including:

  • Consensus Estimates
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.